Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FKBP1A | P62942 | 15/20 | 1.00 |
| ▸ | FKBP5 | Q13451 | 6/20 | 0.89 |
| ▸ | FKBP4 | Q02790 | 3/20 | 0.86 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22451751 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL18448700 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL25501190 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL29672647 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL20136603 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL15764887 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL16809378 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL20791944 | 1.00 | FKBP1A (1.00) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL26508772 | 0.96 | FKBP1A (0.92) | FKBP1AFKBP5FKBP4 | |
| SCHEMBL16975607 | 0.95 | FKBP1A (0.91) | FKBP1AFKBP5FKBP4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 109 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20250035641-A1 | COMPOSITIONS AND METHODS RELATED TO PROTEIN LABELING | THE CHINESE UNIVERSITY OF HONG KONG (CN) | 2025-01-30 | — | — | US | disclosed |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2024-12-05 | — | — | US | disclosed |
| US-20240238426-A1 | PROTEIN ACYLATION MODULATION BY HETEROBIFUNCTIONAL MOLECULES | THE SCRIPPS RESEARCH INSTITUTE | 2024-07-18 | — | — | US | disclosed |
| US-20240229077-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2024-07-11 | — | — | US | disclosed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2024-07-02 | — | — | US | disclosed |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2024-05-28 | — | — | US | disclosed |
| US-11912985-B2 | Methods and compositions for simultaneous editing of both strands of a target double-stranded nucleotide sequence | THE BROAD INSTITUTE, INC. (US) | 2024-02-27 | — | — | US | disclosed |
| US-20230383289-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | THE BROAD INSTITUTE, INC. (US) | 2023-11-30 | — | — | US | disclosed |
| US-20160235730-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160235730-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | DANA-FARBER CANCER INSTITUTE, INC. | 2016-08-18 | — | — | US | disclosed |
| US-20160176916-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| US-20160176916-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2016-06-23 | — | — | US | disclosed |
| US-9260710-B2 | Photocleavable linker | CITY OF HOPE (US) | 2016-02-16 | — | — | US | disclosed |
| US-20150291950-A1 | PHOTOCLEAVABLE LINKER | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2015-10-15 | — | — | US | disclosed |
| US-9096844-B2 | Photocleavable linker | CITY OF HOPE (US) | 2015-08-04 | — | — | US | disclosed |
| US-20140154775-A1 | PHOTOCLEAVABLE LINKER | CITY OF HOPE (US) | 2014-06-05 | — | — | US | disclosed |
| US-8436183-B2 | Synthetic multimerizing agents | ARIAD PHARMACEUTICALS, INC. (US) | 2013-05-07 | — | — | US | disclosed |
| US-8106191-B2 | Compounds based on N- acyl-pipecolyl and N-acyl-prolyl ligand moieties for multimerizing chimeric proteins containing immunophilin-derived domains | ARIAD PHARMACEUTICALS, INC. (US) | 2012-01-31 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12605450-B2 | C3-carbon linked glutarimide Degronimers for target protein degradation | NEDD4, UBE3A, UBE3C | FKBP1A 874/4885FKBP5 732/4885FKBP4 1309/4885 |
| US-20240238426-A1 | PROTEIN ACYLATION MODULATION BY HETEROBIFUNCTIONAL MOLECULES | ACAT2, ACOT7, AADAC | FKBP1A 1012/4885FKBP5 560/4885FKBP4 899/4885 |
| US-12023385-B2 | Tunable endogenous protein degradation with heterobifunctional compounds | DBN1, MYCBP, PSMG3 | FKBP1A 73/4885FKBP5 203/4885FKBP4 301/4885 |
| US-11992531-B2 | C3-carbon linked glutarimide degronimers for target protein degradation | STUB1, UBE3C, UBE3A | FKBP1A 375/4885FKBP5 465/4885FKBP4 588/4885 |
| US-20240398959-A1 | C3-CARBON LINKED GLUTARIMIDE DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | STUB1, UBE3C, UBE3A | FKBP1A 375/4885FKBP5 465/4885FKBP4 588/4885 |
| US-20160235730-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | FKBP1A 224/4885FKBP5 443/4885FKBP4 508/4885 |
| US-20160176916-A1 | METHODS TO INDUCE TARGETED PROTEIN DEGRADATION THROUGH BIFUNCTIONAL MOLECULES | CRBN, MDM2, MYCBP | FKBP1A 224/4885FKBP5 443/4885FKBP4 508/4885 |
| US-20150291950-A1 | PHOTOCLEAVABLE LINKER | DCLRE1A, UACA, HMBS | FKBP1A 163/4885FKBP5 409/4885FKBP4 185/4885 |
| US-20230383289-A1 | METHODS AND COMPOSITIONS FOR PRIME EDITING NUCLEOTIDE SEQUENCES | RNGTT, POLRMT, POLM | FKBP1A 2583/4885FKBP5 3334/4885FKBP4 3044/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.